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Abstract
Background: Despite ethical imperatives, informing research participants about the results of the
studies in which they take part is not often performed. This is due, in part, to the costs and burdens
of communicating with each participant after publication of the results.
Methods: Following the closeout and publication of a randomized clinical trial of saw palmetto for
treatment of symptoms of benign prostatic hyperplasia, patients were invited back to the research
center to participate in a group presentation of the study results.
Results: Approximately 10% of participants attended one of two presentation sessions. Reaction
to the experience of the group presentation was very positive among the attendees.
Conclusion:  A group presentation to research participants is an efficient method of
communicating study results to those who desire to be informed and was highly valued by those
who attended. Prospectively planning for such presentations and greater scheduling flexibility may
result in higher attendance rates.
Trial Registration Number: Clinicaltrials.gov #NCT00037154
Background
Research participants often wish to know the results of the
studies in which they have taken part [1-6]. Though data
on this issue are scant, it appears that providing the results
of research studies to participants is not typical [5,7,8]
leaving many participants, who have born the risks and
burdens of the study, without the information they desire.
It is unclear why more participants are not informed
about the results of their studies. Clearly, some may
choose not to know the study findings, as they may feel
burdened by the implications of receiving the inferior
treatment or that they may be at increased risk for future
adverse outcomes [2,5,9]. For those participants who
desire to learn the results, other, more practical barriers
exist. Results are typically embargoed until publication in
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the peer-reviewed literature, so considerable time may
elapse between the end of the participant-contact phase of
a study and the publication of its results [10,11]; interest
of participants and of study staff in re-contacting partici-
pants may wane over this interval. Perhaps more impor-
tantly, one-on-one personal contact between participants
and study personnel can be very expensive and time-con-
suming and, therefore, may be avoided by many investi-
gators [12].
Despite these understandable barriers, many researchers
feel that participants are entitled to have the option of
being informed about study results, given their contribu-
tions during the investigation; addressing this desire
would be consistent with the principle of "respect for per-
sons" that governs much of the ethical foundation of
health-related research [5,12,13]. Finding ways to permit
interested participants to learn the results of their studies
in ways that do not place burdensome demands on inves-
tigators and staff is essential if we are to conduct research
with full respect for the participants [5].
We report here our experience with a group presentation
of the results of a clinical trial and ways in which this proc-
ess could be adapted and improved in future studies. Oth-
ers have alluded to this method [10] and it is likely that
many investigators have used this technique. However, we
have not found a reference to this strategy previously and
our experience suggests it may serve a useful role in many
research environments.
Methods
The STEP (Saw palmetto Treatment for Enlarged Prostates)
study was a two-arm, randomized, double-blind, placebo-
controlled clinical trial of an extract of the saw palmetto
berry for the treatment of symptoms of benign prostatic
hyperplasia (BPH), funded by the National Institutes of
Health [14]. The 225 participants were men at least fifty
years of age with moderate-to-severe symptoms of BPH
who were randomized to a saw palmetto extract or an iden-
tical-appearing placebo and followed for changes in
symptoms and measures of urinary flow for one year. The
trial showed that the herbal extract was not superior to
placebo in improving symptoms or urinary function. The
study was approved by the institutional review boards
(IRB's) of the University of California, San Francisco, and
the Kaiser Foundation Research Institute; all participants
gave informed consent.
Participants were recruited from the San Francisco Veter-
ans Affairs Medical Center (SFVAMC) and the Kaiser Per-
manente, Northern California (KPNC) health plan.
Immediately following the termination of clinical activi-
ties, all participants were mailed a letter informing them
of their randomization assignment (no study results were
contained in this letter).
Following termination of the trial, the study investigators
decided to hold meetings to present the results to the par-
ticipants. Soon after publication of the trial findings, par-
ticipants were sent a letter inviting them back to the
research center for a presentation describing the results
and were also offered an opportunity to receive a copy of
the published paper [14] and an accompanying editorial
[15]. Participants were asked to call the research center if
they were interested in attending the meeting or desired to
receive a copy of the manuscript. Two meetings were held,
one for participants recruited from each of the two clinical
sites (KPNC and SFVAMC). IRB approval for these post-
trial meetings was obtained from one institution and
waived by the other. The first meeting, for SFVAMC partic-
ipants, was held 2 months after publication of the results
(22 months after the end of the study) and the second
meeting, for KPNC participants, was delayed until 9
months after publication (31 months after the end of the
trial; the second meeting was delayed because of investi-
gator availability, the need for IRB approval, and space
availability). A survey was conducted at the second pres-
entation that assessed the value and perceptions of the
meeting, addressing knowledge learned about the study
from the presentation and the published paper; no formal
validation of the survey instrument was conducted. All
responses to the survey items were measured on 7-point
Likert scales.
At each presentation, copies of the published manuscript
were provided to attendees. A forty-minute overview was
then presented by the principal investigator. The presenta-
tion began with an overview of the disease process (BPH)
and the rationale for conducting the study. This informa-
tion was followed by a description of the study methods,
with careful explanation of randomization, blinding, and
placebos. The study results were then presented, using the
tables and figures from the published manuscript [14].
Finally, the presenter provided his view of the implica-
tions of the results, an overview of future research needs,
and a statement of gratitude to the participants for the
knowledge they helped provide for patients with BPH.
Participants were encouraged to ask questions throughout
the presentation and the investigator remained after the
conclusion of the formal presentation to answer individ-
ual concerns.
Results
Attendance at the two meetings was relatively low. For the
first meeting, 58 letters of invitation were mailed and 13
participants expressed interest in attending but only 3 par-
ticipants actually attended the presentation. For the sec-
ond meeting, 167 invitations were mailed and 30Trials 2008, 9:16 http://www.trialsjournal.com/content/9/1/16
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participants expressed a desire to attend though only 17
participants were present at the meeting (several of the
non-attendees cited scheduling conflicts with the meeting
time). There was a great deal of energetic discussion
among the participants during and after the presentations
and the attendees asked numerous questions during the
meetings. The questions dealt with a desire for more infor-
mation about BPH, the rationales for study methods (ran-
domization, placebos, etc.), the interpretation of the data
(including the statistical aspects), and plans for future
research.
All attendees of the second meeting completed the meet-
ing questionnaire and responses to this survey revealed
that virtually all participants found the presentation valu-
able (Table 1). Responses to items assessing reaction to
the meeting were uniformly positive and all respondents
thought that future studies should include this type of
informational meeting. Informal comments to the pre-
senter after the meeting indicated that several participants
were very grateful for the opportunity to receive the results
and interact with the investigators and other participants.
Among the eight respondents who also had received a
copy of the published paper prior to the meeting, the
mean response to the question, "Did you find the infor-
mation contained in the article understandable?" was sig-
nificantly lower than the mean response to the question,
"How well do you feel you've understood the results of
the STEP study now [after the meeting]?" (5.3 vs. 6.7, p =
0.04).
Discussion
Though little empiric data exist, it is likely that many
research participants prefer not to learn the results of the
studies in which they have taken part [2,5,9]. Others,
however, may be quite interested in obtaining this infor-
mation but several practical barriers have been identified
that may impede providing detailed trial results to indi-
vidual participants [5,7,10,12].
We found that a group presentation of study results was
effective in communicating the results to some partici-
pants and was extremely well received by those who
attended. Among the attendees, views of the value of the
presentation were uniformly enthusiastic and virtually all
felt that the meetings achieved the goals of providing the
results in an easily understood format and affording an
opportunity to have their post-study questions answered.
It should be noted, however, that the low number of par-
ticipants who attended the meeting makes generalization
of our findings to other settings difficult.
Implementation of a group presentation is fairly straight-
forward. Most investigators will have prepared presenta-
tions for other venues (e.g., scientific meetings) that can
be easily adapted to a lay audience; the grant proposal,
IRB application, and published manuscripts also provide
a ready source of tables and graphs for presentation. Per-
haps the greatest barrier is finding available presentation
space and the work of organizing the meeting itself
(which may be made more difficult, as in this case, by the
fact that the study has concluded and the research staff are
no longer available to assist).
As noted, attendance at the meetings was relatively low.
We believe there were several reasons for this, most of
which can be addressed by better organizational efforts.
First, the meetings were held several months after release
of the study results. In our case, this was the result of con-
ceiving the idea for the presentation relatively late, issues
Table 1: Survey of participants attending post-trial meeting.
Question Lower Anchor (= 1) Upper Anchor (= 7) Mean 95% C.I.
How useful did you find this presentation? Not useful at all Extremely useful 6.6 6.3 – 7.0
Did this presentation provide additional information beyond what you 
already knew from the news media?
No Yes 6.7 6.4 – 7.0
How well do you feel you've understood the results of the STEP study now? Not well at all Extremely well 6.7 6.4 – 7.0
Do you feel that you had all your questions answered about the STEP study? No Yes 6.8 6.5 – 7.0
Did your experience with the STEP study make you more or less interested 
in participating in future research studies?
Much less interested Much more interested 6.3 5.5 – 7.0
Did your experience with this meeting make you more or less interested in 
participating in future research studies?
Much less interested Much more interested 6.4 5.6 – 7.0
Should future research studies offer meetings such as this one? No Yes 6.9 6.8 – 7.0
If you received a copy of the published scientific article before this meeting 
(N = 8):
Did you find the information contained in the article understandable? Hard to understand Easy to understand 5.3 4.3 – 6.2
Did you find the information contained in the article useful? Not useful at all Extremely useful 6.0 5.2 – 6.8
Mean responses to survey questions following meeting presentation (N = 17).
Abbreviations:
C.I. = confidence interval
STEP = Saw palmetto treatment for enlarged prostates (study)Trials 2008, 9:16 http://www.trialsjournal.com/content/9/1/16
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in obtaining presentation space, lack of administrative
support for planning and conducting the presentation,
and delays in obtaining IRB approval. It is possible that
presentations given soon after release of findings (and,
therefore, closer to the time of study closeout) might be of
greater appeal to participants, whose interest in the results
may wane over time. Second, we offered only one presen-
tation opportunity for each recruitment site; providing
more than one meeting might have allowed more partici-
pants to attend (as noted, several participants contacted
us, expressing a desire to attend but cited scheduling con-
flicts as the reason for not attending the presentation).
Finally, we did not envision this meeting at the beginning
of the study, when we could have provided more anticipa-
tion for participants and raised expectations and aware-
ness of this opportunity. It should be noted that we did
provide each participant with his randomization assign-
ment after study closeout. While this was appreciated by
many participants (and we received no negative reactions
to this notification), we may have erred in not giving par-
ticipants the choice of whether to receive this information
or not [1].
While our experience suggests that, with some improve-
ments, this method is efficient in providing detailed study
results and opportunity for interaction with minimal bur-
den to study investigators, there are limitations. In partic-
ular, this technique may not be appropriate for studies of
sensitive diagnoses in which anonymity may be impor-
tant to participants. Even for other diagnoses, some partic-
ipants may be uncomfortable appearing in a group
situation with other participants, and alternatives, such as
individual meetings, telephone calls, or mailing results
(published papers and/or detailed summaries), may be
more desirable and should also be considered. Given the
increasing numbers of individuals with internet experi-
ence, one could also consider internet-based distribution
of study results through a secure website and/or posting of
an anonymized "frequently-asked-questions" site for
more interactive distribution of study information to par-
ticipants. Combinations of these methods may provide
the optimal approach to addressing participants' interest
in obtaining study results. It is noteworthy that, among
those few respondents (n = 8) who both attended the
meeting and were provided with the published paper in
advance, comprehension of the study results was signifi-
cantly better as a result of the presentation compared to
the published manuscript, suggesting that technical arti-
cles from the medical literature may be less comprehensi-
ble to participants than information provided through in-
person contact.
While we did not consider it essential to have personal
contact with participants in order to deliver study results,
our experience indicated that the group presentation was
highly valued by virtually all of the attendees, given the
results of the survey and the animated level of discussion
between the participants and the investigator, and among
the participants themselves. Furthermore, many partici-
pants seemed to value the queries of other participants
since specific issues may not have occurred to some partic-
ipants and some individuals may feel reticent to ask ques-
tions of the researchers and appreciate the candidness of
other participants in questioning the investigators. Inter-
estingly, most attendees responded that the experience of
the meeting made them more interested in participating
in future studies, an important ancillary benefit of pro-
moting this type of contact with study participants.
Conclusion
We found that a group presentation of study results was
highly valued by a select group of study participants, and
provided a relatively efficient means of providing results
to these individuals. Several opportunities for improving
our implementation are evident and, with further experi-
ence, greater attendance may result in more participants
feeling that their interests and contributions were well
served by researchers.
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